Decreased cerebral response to inhibitory neurotransmission in alcoholics.
OBJECTIVE
Changes in gamma-aminobutyric acid (GABA)-benzodiazepine receptor function have been implicated in alcohol tolerance, withdrawal, and dependence. The purpose of this study was to investigate whether recently detoxified alcoholic subjects had abnormalities in brain GABA-benzodiazepine receptor function.


METHODS
The effect of 30 micrograms/kg of lorazepam on regional brain glucose metabolism was studied in 12 normal subjects and 10 alcoholic subjects with the use of positron emission tomography and [18F]fluorodeoxyglucose.


RESULTS
Lorazepam decreased whole brain glucose metabolism in both the normal subjects (13% change) and the alcoholic subjects (10% change), and the response was correlated with the concentration of lorazepam in plasma. Whereas the normal and alcoholic subjects showed similar responses to lorazepam in occipital and cerebellar metabolism, the alcoholic subjects showed significantly less of a response than the comparison subjects in the thalamus, basal ganglia, and orbitofrontal cortex. The rate of response in the orbitofrontal cortex was significantly correlated with cerebellar metabolism at baseline.


CONCLUSIONS
The alcoholic subjects had a blunted response to lorazepam that was specific to certain brain regions. The association between cerebellar metabolism and response to lorazepam suggests that the cerebellum may contribute to the decreased sensitivity to lorazepam which was seen in the alcoholic subjects.
Medical Department, Brookhaven National Laboratory, Upton, NY 11973.
N D
ND
Volkow
G J
GJ
Wang
R
R
Hitzemann
J S
JS
Fowler
A P
AP
Wolf
N
N
Pappas
A
A
Biegon
S L
SL
Dewey
D000328:Adult; D000437:Alcoholism / Q000175:diagnosis / Q000378:metabolism* / Q000503:physiopathology; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D002531:Cerebellum / Q000187:drug effects / Q000378:metabolism; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D007839:Functional Laterality / Q000502:physiology; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008140:Lorazepam / Q000097:blood / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009778:Occipital Lobe / Q000187:drug effects / Q000378:metabolism; D011963:Receptors, GABA-A / Q000502:physiology*; D014055:Tomography, Emission-Computed
D011963:Receptors, GABA-A; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose; D005947:Glucose; D008140:Lorazepam